Hemostemix's Vescell.Health Launched In Florida

(MENAFN- Newsfile Corp) Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCellTM (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, today announces it launched VesCell in Florida, a dedicated educational website designed to help physicians and patients understand the benefits of VesCellTM , Hemostemix's groundbreaking autologous stem cell therapy.

Under physician order, following informed consent, Florida's law SB 1768 now permits the use of VesCellTM in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options.

VesCell makes the science of using autologous (patient's own) stem cells understandable to the layman. The site presents complex clinical research in plain, accessible language, while also serving as a trusted repository of 11 peer-reviewed publications that document the safety and efficacy of VesCell across seven clinical trials , including a Phase II double blind randomized clinical trial in Critical Limb Threatening Ischemia (CLTI) .

The site is structured to provide visitors with:

• Clear, patient-friendly explanations of what VesCell is and how it works.

• Evidence-based results from published clinical studies on conditions such as angina, ischemic cardiomyopathy, non ischemic cardiomyopathy, congestive heart failure, peripheral arterial disease, and chronic limb threatening ischemia.

• Localized access for Florida residents, ensuring information is aligned with regional regulatory frameworks and treatment pathways.

"Launching VesCell is about giving patients and their families the information they need, in words they can understand, supported by world-class science," said Thomas Smeenk, CEO of Hemostemix . "By combining plain language with peer-reviewed evidence, we are making the benefits of VesCell clear and approachable for physicians and Floridians who are searching for treatment answers and hope."

With the launch of VesCell, Hemostemix continues its mission of advancing the understanding and accessibility of regenerative medicine while ensuring compliance within federal and state jurisdictional healthcare requirements.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCellTM (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease , chronic limb threatening ischemia , non ischemic dilated cardiomyopathy , ischemic cardiomyopathy , congestive heart failure , and angina . Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science . As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit .

MENAFN04092025004218003983ID1110017861